STOCK TITAN

Lisata Therapeutics sets 1-for-15 reverse split

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Lisata Therapeutics, Inc. (LSTA) will effect a one-for-fifteen reverse stock split at 12:01 a.m. Eastern Time on November 23, 2026. Every 15 shares of common stock issued and outstanding immediately before that time will become one share. The issued and outstanding share count will decrease from approximately 10.8 million to approximately 0.7 million. The split will not change the $0.001 par value per share or the total number of authorized common shares.

Stockholders approved a reverse split ratio between one-for-five and one-for-fifteen, and the board selected one-for-fifteen. Trading on The Nasdaq Capital Market will begin on a split-adjusted basis at market open on November 23 under the existing symbol LSTA. Percentage ownership will not change except for minor changes that may result from fractional-share treatment; holders otherwise entitled to fractions will receive cash based on the November 19 closing price. Convertible, exchangeable, or exercisable securities and rights will be adjusted under their terms.

Item 3.03 Material Modification to Rights of Security Holders Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Reverse split ratio 1-for-15 Selected by the board; effective November 23, 2026
Issued and outstanding shares before split Approximately 10.8 million shares Before the reverse stock split
Issued and outstanding shares after split Approximately 0.7 million shares After the reverse stock split
Effective date November 23, 2026 Effective at 12:01 a.m. Eastern Time
reverse stock split technical
"to effect a one-for-fifteen reverse stock split of the Company’s shares of common stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
par value financial
"without any change to the par value per share of Common Stock"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
fractional share technical
"No fractional shares will be issued in connection with the reverse stock split"
A fractional share is a portion of a single stock that is worth less than one full share, like owning a slice of a pizza instead of the whole pie. It lets investors buy and hold part of expensive stocks or spread small amounts of money across many companies, which helps with diversification and regular investing; dividends and price changes affect fractional shares proportionally, though some rights and trading rules can vary by provider.
split-adjusted basis technical
"Trading of the Common Stock on The Nasdaq Capital Market will commence on a split-adjusted basis"
An adjustment to historical share prices and share counts that reflects past stock splits or reverse splits so that old data lines up with the current number of shares. Think of it like resizing an old photograph so it matches a new frame: it keeps price charts, returns and per‑share metrics comparable over time, which matters to investors who need accurate performance, valuation and trend analysis.
Split Ratio 1-for-15 reverse split
Effective Date November 23, 2026
Shares Before Split 10,800,000
Shares After Split 700,000

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is LSTA’s reverse stock split ratio and when does it take effect?

The reverse split is one-for-fifteen and takes effect November 23, 2026, at 12:01 a.m. Eastern Time. Trading on a split-adjusted basis is scheduled to begin at market open that day under the existing symbol LSTA.

How will fractional shares be handled in LSTA’s reverse split?

Holders otherwise entitled to a fractional share will receive cash based on the fractional share interest multiplied by the November 19, 2026 closing price of LSTA common stock on The Nasdaq Capital Market. No fractional shares will be issued.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 19, 2026

LISATA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 

         
Delaware
 
001-33650
 
22-2343568
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
P.O. Box 173 Liberty Corner, NJ 07938
(Address of principal executive offices, including zip code)
 
(908) 842-0100
(Registrant’s telephone number, including area code)
 
Not Applicable
 
(Former Name or Former Address, if Changed Since Last Report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.001 par value per share
 
LSTA
 
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

1

 
Item 3.03
Material Modification to Rights of Security Holders.
 
To the extent required by Item 3.03 of Form 8-K, the information set forth in Item 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.
 
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
 
On November 19, 2026, Lisata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a one-for-fifteen reverse stock split of the Company’s shares of common stock, par value $0.001 per share (“Common Stock”). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on November 23, 2026 (the “Effective Time”).
 
As previously disclosed, at the Company’s 2026 annual meeting of stockholders held on November 9, 2026, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock at a ratio to be determined by the Company’s Board of Directors (the “Board”) within the range from one-for-five to one-for-fifteen. The Board set the reverse stock split ratio at one-for-fifteen.
 
As a result of the reverse stock split, every fifteen shares of Common Stock issued and outstanding immediately before the Effective Time will be combined into one share of Common Stock, without any change to the par value per share of Common Stock and without any change in the total number of authorized shares of Common Stock. The reverse stock split will not affect any stockholder’s percentage ownership interest in the Company, except for minor changes that may result from the treatment of fractional shares. Outstanding securities or rights convertible into, or exchangeable or exercisable for, the Common Stock will be appropriately adjusted for the reverse stock split in accordance with their terms.
 
No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will receive a cash payment equal to the fractional share interest multiplied by the closing price of the Common Stock on The Nasdaq Capital Market on November 19, 2026, the date of the filing of the Certificate of Amendment.
 
Trading of the Common Stock on The Nasdaq Capital Market will commence on a split-adjusted basis at market open on November 23, 2026 under the existing trading symbol “LSTA”. The new CUSIP number for the Company’s Common Stock following the reverse stock split is 128058 401.
 
The foregoing summary of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Item 8.01
Other Events.
 
On November 19, 2026, the Company issued a press release announcing the reverse stock split and other related information. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
 
Forward-Looking Statements
 
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the effective date of the reverse stock split and date on which the Common Stock will begin trading on a split-adjusted basis. Words such as “expect,” “anticipate,” “plan,” “look forward” and similar expressions identify such statements. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described under “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update them except as required by law.
 
2

 
Item 9.01
Financial Statements and Exhibits
 
(d) Exhibits
 
   
Exhibit Number Exhibit Description
   
3.1
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Lisata Therapeutics, Inc.
   
99.1
Press Release, dated November 19, 2026
   
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)
 
3

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
Lisata Therapeutics, Inc.
 
 
 
Date: November 19, 2026
By:
/s/ David J. Mazzo, Ph.D.
   
David J. Mazzo, Ph.D.
   
Chief Executive Officer
 
 

NASDAQ 0000320017 false --12-31 0000320017 2026-11-19 2026-11-19

Exhibit 99.1
 
LISATA THERAPEUTICS, INC.
Announces Reverse Stock Split Effective NOVEMBER 23, 2026
 
LIBERTY CORNER, N.J., Nov. 19, 2026 – Lisata Therapeutics, Inc. (NASDAQ: LSTA) (“Lisata” or the “Company”) today announced a one-for-fifteen reverse stock split of its common stock. The Company’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market at the market open on November 23, 2026 under the existing trading symbol “LSTA”. The new CUSIP number for the Company’s common stock following the reverse stock split will be 128058 401.
 
At the Company’s 2026 annual meeting of stockholders held on November 9, 2026, the Company’s stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of its common stock at a ratio to be determined by the Company’s board of directors within the range from one-for-five to one-for-fifteen. The Company’s board of directors approved the reverse stock split at the ratio of one-for-fifteen.
 
At the effective time of the reverse stock split, every fifteen shares of the Company’s common stock then issued and outstanding will be combined into one share of common stock, without any change to the par value per share and without any change in the total number of authorized shares of common stock. The number of issued and outstanding shares of common stock will be reduced from approximately 10.8 million shares to approximately 0.7 million shares. The reverse stock split will not affect any stockholder’s percentage ownership interest in the Company, except for minor changes that may result from the treatment of fractional shares.
 
No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will receive a cash payment equal to the fractional share interest multiplied by the closing price of the Company’s common stock on The Nasdaq Capital Market on November 19, 2026, the date of the filing of the certificate of amendment to the Company’s amended and restated certificate of incorporation.
 
Outstanding securities or rights convertible into, or exchangeable or exercisable for, the Company’s common stock will be appropriately adjusted for the reverse stock split in accordance with their terms.
 
About Lisata Therapeutics
 
Lisata Therapeutics is a clinical-stage pharmaceutical company. Following its acquisition of Marea Therapeutics, Lisata’s lead product candidate is MAR001, which is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The Company is also advancing MAR002 for the treatment of acromegaly. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. For more information on the Company, please visit www.lisata.com.
 
Forward-Looking Statements
 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the effective date of the reverse stock split and date on which the Company’s common stock will begin trading on a split-adjusted basis. Words such as “expect,” “anticipate,” “plan,” “look forward” and similar expressions identify such statements. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described under “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.
 
Lisata:
Investors and Media:
John Menditto
jmenditto@lisata.com

Filing Exhibits & Attachments

5 documents

Keep reading